Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 1
2009 1
2014 1
2017 1
2018 2
2019 2
2020 2
2021 5
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Check(point) or checkmate for acute myeloid leukemia?
Niyongere S, Rapoport AP. Niyongere S, et al. Haematologica. 2021 May 1;106(5):1230-1231. doi: 10.3324/haematol.2020.277103. Haematologica. 2021. PMID: 33538155 Free PMC article. No abstract available.
Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A, Kapadia B, Bollino D, Bhandary B, Baer MR, Niyongere S, Strovel ET, Kaizer H, Chang E, Choi EY, Ma X, Tighe KM, Carter-Cooper B, Moses BS, Civin CI, Mahurkar A, Shetty AC, Gartenhaus RB, Kamangar F, Lapidus RG. Emadi A, et al. Among authors: niyongere s. Leukemia. 2021 Jul;35(7):1907-1924. doi: 10.1038/s41375-020-01080-6. Epub 2020 Nov 16. Leukemia. 2021. PMID: 33199836 Free PMC article.
Therapy-related B-lymphoblastic leukemia after multiple myeloma.
Kallen ME, Koka R, Singh ZN, Ning Y, Kocoglu MH, Badros AZ, Niyongere S, Duong VH, Emadi A, Baer MR. Kallen ME, et al. Among authors: niyongere s. Leuk Res Rep. 2022 Nov 1;18:100358. doi: 10.1016/j.lrr.2022.100358. eCollection 2022. Leuk Res Rep. 2022. PMID: 36353199 Free PMC article.
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
Scarpa M, Singh P, Bailey CM, Lee JK, Kapoor S, Lapidus RG, Niyongere S, Sangodkar J, Wang Y, Perrotti D, Narla G, Baer MR. Scarpa M, et al. Among authors: niyongere s. Mol Cancer Ther. 2021 Apr;20(4):676-690. doi: 10.1158/1535-7163.MCT-20-0663. Epub 2021 Feb 10. Mol Cancer Ther. 2021. PMID: 33568357 Free PMC article.
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Baer MR, et al. Among authors: niyongere s. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. Clin Cancer Res. 2022. PMID: 35091444 Free PMC article. Clinical Trial.
Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK, Chatterjee A, Scarpa M, Bailey CM, Niyongere S, Singh P, Mustafa Ali MK, Kapoor S, Wang Y, Silvestri G, Baer MR. Lee JK, et al. Among authors: niyongere s. Cancer Res Commun. 2024 Feb 16;4(2):431-445. doi: 10.1158/2767-9764.CRC-23-0379. Cancer Res Commun. 2024. PMID: 38284896 Free PMC article.
Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
Sanchez-Petitto G, Goloubeva OG, Masur J, Childress J, Iqbal T, An M, Muhammad S, Lawson J, Li G, Barr B, Emadi A, Law JY, Lee ST, Duong VH, Baer MR, Niyongere S. Sanchez-Petitto G, et al. Among authors: niyongere s. Leuk Res. 2024 Mar;138:107456. doi: 10.1016/j.leukres.2024.107456. Epub 2024 Feb 20. Leuk Res. 2024. PMID: 38442593
24 results